The pill lowers ovarian cancer risk, even for smokers

January 18, 2018

(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

According to the study from the U.S. National Cancer Institute, these trends were also observed for endometrial as well.

Long-term use of the was linked to reductions in risk for both cancers, and this was "generally consistent across health behaviors," according to a team led by Kara Michels, a cancer institute epidemiologist.

The researchers looked at data from a U.S. study that tracked the health of from 1995 to 2011. At least 100,000 of the women said they were using an oral contraceptive at the beginning of the study.

Michels' group found a 40 percent reduction in the risk of for women who used the pill for 10 years or more. Furthermore, that benefit was similar for smokers and nonsmokers, and for slim and heavier women, the investigators noted.

As for —tumors of the uterine lining—the benefit was even greater for women with less healthy lifestyle habits.

For example, women who smoked experienced a 53 percent drop in risk for endometrial cancer while on an oral contraceptive. And obese women who were on the pill saw an even greater benefit—a 64 percent reduction in risk for endometrial cancers, the team reported.

However, long-term use of the pill appeared to have no effect on a woman's odds for either breast or colon cancers.

Just how might hormonal contraception shield women from ovarian and endometrial tumors? According to Michels' group, because the pill supplies its own dose of one hormone, progestin, long-term use might then trigger a reduction in a second hormone, estradiol, "across the menstrual cycle."

Exposure to such hormones has been linked to raised rates of certain cancers.

One cancer specialist who reviewed the findings said they expand on existing research.

"This study confirms that long-term use [of the pill] causes a profound reduction in the risk of ovarian and endometrial cancers," said Dr. Stephen Rubin, chief of gynecologic oncology at Fox Chase Cancer Center in Philadelphia.

Ovarian cancer is a "silent killer" because it is often detected only in its later stages. According to the American Cancer Society, more than 22,000 U.S. women will receive a diagnosis of the disease in 2018, and it will claim more than 14,000 lives.

Endometrial cancer is less lethal, but more common. According to the cancer society, more than 63,000 women will be diagnosed with such tumors this year, while about 11,000 will die from the disease.

The new study was published Jan. 18 in JAMA Oncology.

Explore further: Women who take the pill protected from some cancers for up to thirty years

More information: Stephen Rubin, M.D., professor and chief, division of gynecologic oncology, and
Grotzinger-Raab Chair in Surgical Oncology, Fox Chase Cancer Center, Philadelphia; Jan. 18, 2018, JAMA Oncology

Find out more about ovarian cancer at the American Cancer Society.

Related Stories

Women who take the pill protected from some cancers for up to thirty years

March 22, 2017
Women who have taken the oral contraceptive pill are protected from some types of cancer for as long as thirty years according to new research from The University of Aberdeen.

Know the risks, warning signs of ovarian cancer

January 19, 2017
(HealthDay)—Women need to be aware their risk for ovarian cancer increases with age. Half of all cases affect women age 63 or older, according to specialists at Fox Chase Cancer Center in Philadelphia.

Thousands of womb cancers prevented by the pill, study says

August 4, 2015
The contraceptive pill has prevented some 200,000 cases of womb cancer over the last decade in rich nations alone, according to research published Wednesday.

Endometrial ablation doesn't increase cancer risk

August 14, 2017
(HealthDay)—For women in Finland, endometrial ablation is not associated with increased risk of endometrial or breast cancer, according to a study published in the September issue of Obstetrics & Gynecology.

Study: Birth Pill Protects Against Ovarian Cancer

January 25, 2008
The contraceptive Pill gives women substantial and long-lasting protection against ovarian cancer, according to a new report led by Oxford scientists published in The Lancet.

Risk of endometrial cancer down with intentional weight loss

February 7, 2017
(HealthDay)—Losing weight is associated with a significantly lower risk of endometrial cancer, and that benefit appears to be greatest in obese women, according to a study published online Feb. 6 in the Journal of Clinical ...

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.